Treatment of post-transplant diabetic patients.
Renal failure and the need for renal transplantation are more prevalent among patients with diabetes than among other patient groups. Immunosuppressive treatment regimens for post-transplant patients are reviewed, with special emphasis on diabetic patients. The major drugs used are cyclosporine, corticosteroids, azathioprine, antithymocyte or antilymphocyte globulins, and muromonab-CD3 (a monoclonal antibody). Their mechanisms of action, drug interactions, clinical uses in transplantation, and toxicity are reviewed. Some of these drugs will change a diabetic patient's requirements for insulin or oral hypoglycemic agents, and glycemic control during the post-transplant period needs careful monitoring.
College of Pharmacy, Washington State University, Spokane.
J R
JR
White
R K
RK
Campbell
D003920:Diabetes Mellitus / Q000628:therapy*; D003928:Diabetic Nephropathies / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation
D007166:Immunosuppressive Agents